InflaRx Completes Enrollment of Vilobelimab Phase III Study in Severe COVID-19GlobeNewsWire • 10/12/21
InflaRx to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceGlobeNewsWire • 09/09/21
InflaRx to Proceed with Pivotal Development for Vilobelimab in Hidradenitis Suppurativa with New Primary EndpointGlobeNewsWire • 09/08/21
InflaRx's Vilobelimab Shows Encouraging Signs Of Drug Activity In Mid-Stage Study With Dermatological Ulcer PatientsBenzinga • 08/10/21
InflaRx Announces Positive Data from Second Interim Analysis of Ongoing Phase IIa Open Label Study with Vilobelimab in Pyoderma GangraenosumGlobeNewsWire • 08/10/21
InflaRx Doses First Patient in Multicenter Phase II Clinical Trial in Cutaneous Squamous Cell Carcinoma with VilobelimabGlobeNewsWire • 06/08/21
InflaRx's Vilobelimab Hits Primary Endpoint Goal In Late-Stage ANCA-Associated Vasculitis StudyBenzinga • 05/12/21
InflaRx Announces Positive Topline Results for Vilobelimab from the U.S. Phase II ANCA-Associated Vasculitis IXPLORE StudyGlobeNewsWire • 05/11/21
InflaRx Completes Enrollment of Vilobelimab Phase IIa Study in Pyoderma GangraenosumGlobeNewsWire • 04/15/21
InflaRx Announces Closing of $75 Million Public Offering of Common Shares and One-Year WarrantsGlobeNewsWire • 03/01/21
InflaRx Announces Pricing of $75 Million Public Offering of Common Shares and One-Year WarrantsGlobeNewsWire • 02/25/21
InflaRx's Vilobelimab Suppresses Inflammation In Mid-Stage Chronic Skin Disorder StudyBenzinga • 02/11/21
InflaRx Announces Presentation of New C5a and Vilobelimab (IFX-1) Data from Phase IIB SHINE Study at the 2021 Virtual European Hidradenitis Suppurativa Foundation ConferenceGlobeNewsWire • 02/11/21